Sign up to get each new magazine issue delivered to your inbox

September 2022

The United Kingdom has been building its own regulatory framework to approve and assess drugs post-Brexit. But pharma’s appetite for navigating multiple health technology assessments for its therapies in Europe remains unclear. In next month’s issue, we take a look at how things have changed in the last few years, and what can be expected in the near future.  


The September issue will also feature a quantitative look at partial orphan drugs—those expensive therapies that are first approved to treat rare disorders, and then have their labels expanded to include common chronic conditions.  


All this plus the latest trends and innovations in the pharma industry, as well as up-to-date analysis and insight from GlobalData experts.

EDITORIAL

Editor | Manasi Vaidya

Writers | Adam Zamecnik, Irena Maragkou, William Newton, Manasi Vaidya, Urtė Fultinavičiūtė

Magazine Designer | Will Ingham
Graphic Designers | Anett Arc, Ashley McPherson, Tyrrell Lowe, Noemi Balint, Martina Labaiova
Lead Designer | John Hammond 

Publisher | Susanne Hauner

Advertising

Sales Manager | Tom McCormick
+44 207 8669440

Pharma Technology Focus is powered by H5mag

Read past issues of Pharma Technology Focus HERE

Copyright 2022 NRi Digital, a trading division of Verdict Media Ltd. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.